The small molecule agonist of TrkB 7,8-dihydroxyflavone (7,8-DHF) has been developed and tested pre-clinically for the treatment of a range of neurodegenerative diseases and injuries including: traumatic brain injury, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, and stroke [5–10]. This evidence concerns the gene NTRK2 and neurodegenerative disease.